165 related articles for article (PubMed ID: 30051771)
1. Computational insights into the interaction mechanism of transcription cofactor vestigial-like protein 4 binding to TEA domain transcription factor 4 by molecular dynamics simulation and molecular mechanics generalized Born/surface area) calculation.
Gao J; Zhang Y; Chen H; Chen Q; Feng D; Zhang L; Li C
J Biomol Struct Dyn; 2019 Jul; 37(10):2538-2545. PubMed ID: 30051771
[TBL] [Abstract][Full Text] [Related]
2. The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex.
Zhang W; Xu J; Li J; Guo T; Jiang D; Feng X; Ma X; He L; Wu W; Yin M; Ge L; Wang Z; Ho MS; Zhao Y; Fei Z; Zhang L
J Biol Chem; 2018 Nov; 293(44):17119-17134. PubMed ID: 30209132
[TBL] [Abstract][Full Text] [Related]
3. DNA-binding mechanism of the Hippo pathway transcription factor TEAD4.
Shi Z; He F; Chen M; Hua L; Wang W; Jiao S; Zhou Z
Oncogene; 2017 Jul; 36(30):4362-4369. PubMed ID: 28368398
[TBL] [Abstract][Full Text] [Related]
4. Molecular dynamics simulations study of influence of Tyr422Ala mutation on transcriptional enhancer activation domain 4 (TEAD4) and transcription co-activators complexes.
Niu RJ; Zheng QC; Zhang HX
J Theor Biol; 2019 Jul; 472():27-35. PubMed ID: 30978352
[TBL] [Abstract][Full Text] [Related]
5. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer.
Kim JY; Kim EK; Lee WM; Hong YO; Lee H
APMIS; 2020 Oct; 128(10):543-551. PubMed ID: 32794608
[TBL] [Abstract][Full Text] [Related]
6. OTUD6A orchestrates complex modulation of TEAD4-mediated transcriptional programs.
Kim HJ; Choi Y; Lee Y; Hwangbo M; Kim J
FEBS Lett; 2024 May; 598(9):1045-1060. PubMed ID: 38594215
[TBL] [Abstract][Full Text] [Related]
7. Rational Design and Intramolecular Cyclization of Hotspot Peptide Segments at YAP-TEAD4 Complex Interface.
Zhang D; He D; Pan X; Liu L
Protein Pept Lett; 2020; 27(10):999-1006. PubMed ID: 32286937
[TBL] [Abstract][Full Text] [Related]
8. Biochemical properties of VGLL4 from Homo sapiens and Tgi from Drosophila melanogaster and possible biological implications.
Mesrouze Y; Meyerhofer M; Zimmermann C; Fontana P; Erdmann D; Chène P
Protein Sci; 2021 Sep; 30(9):1871-1881. PubMed ID: 34075638
[TBL] [Abstract][Full Text] [Related]
9. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
Jiao S; Wang H; Shi Z; Dong A; Zhang W; Song X; He F; Wang Y; Zhang Z; Wang W; Wang X; Guo T; Li P; Zhao Y; Ji H; Zhang L; Zhou Z
Cancer Cell; 2014 Feb; 25(2):166-80. PubMed ID: 24525233
[TBL] [Abstract][Full Text] [Related]
10. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
Jiao S; Li C; Hao Q; Miao H; Zhang L; Li L; Zhou Z
Nat Commun; 2017 Jan; 8():14058. PubMed ID: 28051067
[TBL] [Abstract][Full Text] [Related]
11. HOXB13 suppresses proliferation, migration and invasion, and promotes apoptosis of gastric cancer cells through transcriptional activation of VGLL4 to inhibit the involvement of TEAD4 in the Hippo signaling pathway.
Geng H; Liu G; Hu J; Li J; Wang D; Zou S; Xu X
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34396425
[TBL] [Abstract][Full Text] [Related]
12. The surprising features of the TEAD4-Vgll1 protein-protein interaction.
Mesrouze Y; Hau JC; Erdmann D; Zimmermann C; Fontana P; Schmelzle T; Chène P
Chembiochem; 2014 Mar; 15(4):537-42. PubMed ID: 24504694
[TBL] [Abstract][Full Text] [Related]
13. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs.
Deng X; Fang L
Am J Cancer Res; 2018; 8(6):932-943. PubMed ID: 30034932
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
Zeng Y; Stauffer S; Zhou J; Chen X; Chen Y; Dong J
J Biol Chem; 2017 Sep; 292(36):15028-15038. PubMed ID: 28739871
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of YAP recognition by TEAD4 in the hippo pathway.
Chen L; Chan SW; Zhang X; Walsh M; Lim CJ; Hong W; Song H
Genes Dev; 2010 Feb; 24(3):290-300. PubMed ID: 20123908
[TBL] [Abstract][Full Text] [Related]
16. VGLL4 Protects against Oxidized-LDL-Induced Endothelial Cell Dysfunction and Inflammation by Activating Hippo-YAP/TEAD1 Signaling Pathway.
Xu K; Zhao H; Qiu X; Liu X; Zhao F; Zhao Y
Mediators Inflamm; 2020; 2020():8292173. PubMed ID: 33456372
[TBL] [Abstract][Full Text] [Related]
17. YAP-VGLL4 antagonism defines the major physiological function of the Hippo signaling effector YAP.
Cai J; Choi K; Li H; Pulgar Prieto KD; Zheng Y; Pan D
Genes Dev; 2022 Nov-Dec 1; 36(21-24):1119-1128. PubMed ID: 36522128
[TBL] [Abstract][Full Text] [Related]
18. Molecular design and rational optimization of synergistic effect between the two wings of a roughly orthogonal cation-π-π stacking system at nasopharyngeal carcinoma YAP1-TEAD4 parallel Helix-Helix interaction interface.
Zhu H; Xu S; Wu J; Hu J; Mao X
J Mol Recognit; 2022 Dec; 35(12):e2986. PubMed ID: 36326001
[TBL] [Abstract][Full Text] [Related]
19. Dual function of VGLL4 in muscle regeneration.
Feng X; Wang Z; Wang F; Lu T; Xu J; Ma X; Li J; He L; Zhang W; Li S; Yang W; Zhang S; Ge G; Zhao Y; Hu P; Zhang L
EMBO J; 2019 Sep; 38(17):e101051. PubMed ID: 31328806
[TBL] [Abstract][Full Text] [Related]
20. Depletion of VGLL4 Causes Perinatal Lethality without Affecting Myocardial Development.
Sheldon C; Farley A; Ma Q; Pu WT; Lin Z
Cells; 2022 Sep; 11(18):. PubMed ID: 36139407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
